Cohort Study on Biomarkers of Cognitive Disorders in China
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Biomarkers
- Sponsor
- Cuibai Wei，Clinical Professor
- Enrollment
- 3000
- Locations
- 1
- Primary Endpoint
- Rate of change in global cognition as measured by Clinical Dementia Rating (CDR).
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI cohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc. Establishing standardized and shared longitudinal follow-up dementia cohorts and clinical database is an essential challenge for constructing dementia cohort in China. Moreover, there is a lack of large-scale prospective longitudinal follow-up cohorts within the Chinese population that cover subjective cognitive decline (SCD) to explore biomarkers with diagnostic and early warning value for different kinds of dementia and pre-dementia stages. The study will rely on the dementia cohort based on Chinese population to explore the biological phenotype characteristics of the pre-dementia stage and different dementia subtypes, and observe the dynamic change rules of the dementia cohort vertically, so as to foster early intervention and improve prognosis for individuals with dementia.
Detailed Description
The 3000 patients with pre-dementia stage and different dementia subtypes will be enrolled in this study, and data will be collected in the baseline including demographics, clinical symptoms, assessment of neuropsychology, neuroimaging, neuroelectrophysiology, blood samples, cerebrospinal fluid, etc. The changes of these data were dynamically observed through an annual follow-up. According to the neuropsychological evaluation results of follow-up, the subjects were divided into dementia progression (dementia-P) and dementia stabilization (dementia-S). Difference in clinical phenotype, neuropsychology, electrophysiology, neuroimaging, and body fluid multi-omics indicators between the two subtypes were compared and analyzed. The neuropsychological testes in patients with dementia included some neuropsychological scales such as, Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), etc. Multi-model neuroimaging evaluation screen the candidate neuroimaging markers, including structure and functional brain magnetic resonance imaging (MRI), Diffusion tensor image (DTI), 18 F-2-fluro-D-deoxy-glucose-positron emission tomography (18F-FDG-PET)，Amyloid-PET and tau-PET. To exploring neuroelectrophysiology biomarkers collect the data on polysomnography, resting state electroencephalogram, and evoked potentials (P1, N1, P2, N2, etc.). ELISA, SIMOA and other analytical methods were used to detect the contents related to dementia progression in the blood, cerebrospinal fluid, urine, saliva and feces. Multi-dimensional screening and identifying biomarkers of disease diagnosis and progression in all stages, from subjective cognitive impairment to mild cognitive impairment to dementia, in line with the characteristics of the Chinese population.
Investigators
Cuibai Wei，Clinical Professor
Xuanwu Hospital, Capital Medical University
Xuanwu Hospital, Beijing
Eligibility Criteria
Inclusion Criteria
- •Male or female patients aged ≥40 and ≤90years;
- •Chief complaint or others describe a cognitive decline;
- •Ability to communicate in Chinese;
- •The patients and their families were informed and signed the informed consent.
Exclusion Criteria
- •MMSE\<10;
- •There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);
- •There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
- •Suffering from a disease that cannot cooperate with the completion of cognitive examination;
- •There are contraindications to nuclear magnetic resonance;
- •There is mental and neurodevelopmental delay;
- •Refuse to draw blood;
- •Refuse to sign the informed consent.
Outcomes
Primary Outcomes
Rate of change in global cognition as measured by Clinical Dementia Rating (CDR).
Time Frame: 10 years
Assess statistically significant difference in score between dementia-P and dementia-S using the neuropsychological scales CDR. CDR, a multidimensional scale for dementia severity, which scored 0-3, with higher scores indicating worse functioning.
Secondary Outcomes
- Rate of change in the severity of cognitive impairment as assessed by Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-cog).(10 years)
- Rate of change in activities of daily living as assessed by Alzheimer's Disease Cooperative Study-Activity of Daily Living (ADCS-ADL).(10 years)
- Rate of change in global cognition as measured by Montreal Cognitive Assessment (MoCA)(10 years)
- Rate of change in language function as assessed by Boston Naming Test (BNT).(10 years)
- Rate of change in global cognition as measured by Mini-Mental State Examination (MMSE)(10 years)
- Rate of change in memory function as assessed by World Health Organization-University of California, Los Angeles, auditory verbal learning test (WHO-UCLA AVLT).(10 years)
- Rate of change in psychobehavioral symptoms as assessed by Neuropsychiatric Inventory (NPI).(10 years)